LUCIUS 卢修斯 克性替尼 Crizotinib转移性癌症

克性替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Crizotinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:
Each LuciCrizcapsule contains

LUCiUS

转移性癌症

Indication

HARMACEUTICALS

LuciCriz is for the treatment of patients with
metastatic non-small cell lung cancer

LUCICRIZ

Dosage and Use:

The tecommen
The recommended dosage is 250 mg orally
Capsules should be swallowed whole & no

Crizotinib Capsules

chewed or eruiched.
Storage: in a dry place and store at 20°Cto
25°C.

250mg

FDA批准

Keep medicine out of the reach of Children.
Do not administered LuciCriz in Pregnancy
and Lactation patient treatment.
PLEASE SEE PACKAGE INSER
Manufactured and Marketed by

LUCIUS

Thongmang village. Xaythany district,
Vientiane Capital, Laos

权威认证

www.lucius.na

Warning and Precaution: Tohe cold
prescripuion of a kegistered
stonly, and as dirested by the

60Capsules

Rx Only

口碑质量

适应症:

用于治疗转移性癌症(NSCLC)患者,其肿瘤为间变性淋
巴瘤激酶(ALK)或ROS1-阳性。
推荐剂量:

1、口服250mg,每日口服两次,每次250mg;
2、肾功能损害:不需要透析的严重肾功能损害(肌酐清除
率<30mL/min)患者,每日口服1次:每次250mg。